- Home
- / TC BioPharm
TC BioPharm
Stock Price
$1.6
2024-10-29
Market Capitalization
$926.7 K
2024-10-29
TC BioPharm Summary
Company Summary
- Overview
- TC Biopharm (Holdings) is a clinical-stage cell therapy company developing immunotherapy products. It offers its proprietary allogeneic gamma delta T (GD-T) cell platform for the treatment of blood cancers. In addition, the company specializes in genetically modified chimeric antigen receptor-modified T cell (CAR-T) products for the treatment of solid cancers.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Holytown, GB | view all locations
- Website
- https://www.tcbiopharm.com/
- Cybersecurity rating
Table of Contents
Key People
Angela Scott, Co-Founder and Chief Operating Officer
Michael Leek, Co-Founder and Executive Chairman
Martin Thorp, Chief Financial Officer
LocationsView all
4 locations detected
Holytown, Scotland HQ
United Kingdom
Maxim Park, Parklands Way, Eurocentral
Leiden, ZH
Netherlands
Bargelaan 200
Edinburgh, Scotland
United Kingdom
Pentlands Science Park, Bush Loan
London, England
United Kingdom
2 Riding House St, Marylebone
TC BioPharm Financials
Summary Financials
- Net income (FY, 2023)
- (£5.9M)
- Cash (FY, 2023)
- £2.5M
- EBIT (FY, 2023)
- (£14.9M)
- Enterprise value
- ($1.5M)